Detailed information for compound 456013

Basic information

Technical information
  • TDR Targets ID: 456013
  • Name: (8R,9S,10S,13S,14S,17S)-10-ethenyl-17-hydroxy -13-methyl-1,2,6,7,8,9,11,12,14,15,16,17-dode cahydrocyclopenta[a]phenanthren-3-one
  • MW: 300.435 | Formula: C20H28O2
  • H donors: 1 H acceptors: 2 LogP: 3.6 Rotable bonds: 1
    Rule of 5 violations (Lipinski): 1
  • SMILES: C=C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2O)C
  • InChi: 1S/C20H28O2/c1-3-20-11-8-14(21)12-13(20)4-5-15-16-6-7-18(22)19(16,2)10-9-17(15)20/h3,12,15-18,22H,1,4-11H2,2H3/t15-,16-,17-,18-,19-,20-/m0/s1
  • InChiKey: QIMSMVYRWNZWBL-RABCQHRBSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • (8R,9S,10S,13S,14S,17S)-17-hydroxy-13-methyl-10-vinyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens estrogen receptor 1 Starlite/ChEMBL References
Homo sapiens estrogen receptor 2 (ER beta) Starlite/ChEMBL References
Homo sapiens androgen receptor Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Loa Loa (eye worm) hypothetical protein estrogen receptor 2 (ER beta) 495 aa 418 aa 25.8 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Echinococcus multilocularis farnesyl pyrophosphate synthase 0.0451 1 1
Trichomonas vaginalis geranylgeranyl pyrophosphate synthase, putative 0.0451 1 0.5
Trypanosoma cruzi farnesyl pyrophosphate synthase, putative 0.0451 1 1
Entamoeba histolytica geranylgeranyl pyrophosphate synthase, putative 0.0114 0.0582 0.5
Mycobacterium tuberculosis Probable geranylgeranyl pyrophosphate synthetase IdsA2 (ggppsase) (GGPP synthetase) (geranylgeranyl diphosphate synthase) 0.0451 1 1
Mycobacterium leprae PROBABLE POLYPRENYL-DIPHOSPHATE SYNTHASE GRCC1 (POLYPRENYL PYROPHOSPHATE SYNTHETASE) 0.0114 0.0582 0.5
Echinococcus multilocularis arachidonate 5 lipoxygenase 0.0133 0.1118 0.0569
Schistosoma mansoni geranylgeranyl pyrophosphate synthase 0.0114 0.0582 0.0582
Trichomonas vaginalis geranylgeranyl pyrophosphate synthase, putative 0.0451 1 0.5
Leishmania major farnesyl pyrophosphate synthase 0.0451 1 1
Chlamydia trachomatis geranylgeranyl pyrophosphate synthase 0.0114 0.0582 0.5
Entamoeba histolytica bifunctional short chain isoprenyl diphosphate synthase, putative 0.0114 0.0582 0.5
Treponema pallidum octaprenyl-diphosphate synthase 0.0114 0.0582 0.5
Echinococcus granulosus farnesyl pyrophosphate synthase 0.0451 1 1
Echinococcus granulosus arachidonate 5 lipoxygenase 0.0133 0.1118 0.0569
Schistosoma mansoni glutathione synthetase 0.0114 0.0582 0.0582
Plasmodium falciparum geranylgeranyl pyrophosphate synthase, putative 0.0451 1 1
Entamoeba histolytica geranylgeranyl pyrophosphate synthetase, putative 0.0114 0.0582 0.5
Schistosoma mansoni lipoxygenase 0.0133 0.1118 0.1118
Mycobacterium ulcerans geranylgeranyl pyrophosphate synthase 0.0451 1 1
Schistosoma mansoni trans-prenyltransferase 0.0114 0.0582 0.0582
Mycobacterium ulcerans geranylgeranyl pyrophosphate synthase 0.0451 1 1
Wolbachia endosymbiont of Brugia malayi geranylgeranyl pyrophosphate synthase 0.0114 0.0582 0.5
Schistosoma mansoni hypothetical protein 0.0297 0.5692 0.5692
Loa Loa (eye worm) polyprenyl synthetase 0.0451 1 1
Trypanosoma cruzi farnesyl pyrophosphate synthase 0.0451 1 1
Wolbachia endosymbiont of Brugia malayi geranylgeranyl pyrophosphate synthase 0.0114 0.0582 0.5
Toxoplasma gondii polyprenyl synthetase superfamily protein 0.0451 1 1
Trypanosoma brucei farnesyl pyrophosphate synthase 0.0451 1 1
Schistosoma mansoni farnesyl pyrophosphate synthase 0.0451 1 1
Giardia lamblia Farnesyl diphosphate synthase 0.0451 1 0.5
Trichomonas vaginalis geranylgeranyl diphosphate synthase, putative 0.0451 1 0.5
Plasmodium vivax geranylgeranyl pyrophosphate synthase 0.0451 1 1
Trypanosoma brucei RNA helicase, putative 0.0297 0.5692 0.5426

Activities

Activity type Activity value Assay description Source Reference
Activity (functional) = 12 % Agonist activity at ERalpha expressed in HEK293 cells by transactivation assay ChEMBL. 17890084
Activity (functional) = 12 % Agonist activity at ERalpha expressed in HEK293 cells by transactivation assay ChEMBL. 17890084
Activity (functional) = 78 % Agonist activity at ERbeta expressed in HEK293 cells by transactivation assay ChEMBL. 17890084
Activity (functional) = 78 % Agonist activity at ERbeta expressed in HEK293 cells by transactivation assay ChEMBL. 17890084
EC50 (functional) = 379 nM Agonist activity at human recombinant ERbeta expressed in HEK293 cells by transactivation assay ChEMBL. 17448656
EC50 (functional) = 379 nM Agonist activity at human recombinant ERbeta expressed in HEK293 cells by transactivation assay ChEMBL. 17448656
EC50 (functional) = 380 nM Agonist activity at ERbeta expressed in HEK293 cells by transactivation assay ChEMBL. 17890084
EC50 (functional) = 380 nM Agonist activity at ERbeta expressed in HEK293 cells by transactivation assay ChEMBL. 17890084
EC50 (functional) > 1000 nM Agonist activity at human recombinant ERalpha expressed in HEK293 cells by transactivation assay ChEMBL. 17448656
EC50 (functional) > 1000 nM Agonist activity at ERalpha expressed in HEK293 cells by transactivation assay ChEMBL. 17890084
EC50 (functional) > 1000 nM Agonist activity at human recombinant ERalpha expressed in HEK293 cells by transactivation assay ChEMBL. 17448656
EC50 (functional) > 1000 nM Agonist activity at ERalpha expressed in HEK293 cells by transactivation assay ChEMBL. 17890084
IC50 (binding) = 7.9 nM Binding affinity to androgen receptor ChEMBL. 17448656
IC50 (binding) = 7.9 nM Binding affinity at AR ChEMBL. 17890084
IC50 (binding) = 7.9 nM Binding affinity to androgen receptor ChEMBL. 17448656
IC50 (binding) = 7.9 nM Binding affinity at AR ChEMBL. 17890084
IC50 (binding) = 780 nM Binding affinity at human recombinant ERbeta ChEMBL. 17890084
IC50 (binding) = 780 nM Binding affinity at human recombinant ERbeta ChEMBL. 17890084
IC50 (binding) = 782 nM Binding affinity to human recombinant ERbeta by scintillation proximity assay ChEMBL. 17448656
IC50 (binding) = 782 nM Binding affinity to human recombinant ERbeta by scintillation proximity assay ChEMBL. 17448656
IC50 (binding) > 10000 nM Binding affinity to human recombinant ERalpha by scintillation proximity assay ChEMBL. 17448656
IC50 (binding) > 10000 nM Binding affinity at human recombinant ERalpha ChEMBL. 17890084
IC50 (binding) > 10000 nM Binding affinity to human recombinant ERalpha by scintillation proximity assay ChEMBL. 17448656
IC50 (binding) > 10000 nM Binding affinity at human recombinant ERalpha ChEMBL. 17890084
Ratio EC50 (binding) > 2.6 Selectivity for ERbeta over ERalpha by transactivation assay ChEMBL. 17890084
Ratio IC50 (binding) = 0.01 Ratio of IC50 for androgen receptor to IC50 for human ERbeta ChEMBL. 17448656
Ratio IC50 (binding) = 0.01 Selectivity for human recombinant ERbeta over AR ChEMBL. 17890084
Ratio IC50 (binding) > 2.6 Ratio of EC50 for human ERalpha to EC50 for human ERbeta ChEMBL. 17448656
Ratio IC50 (binding) > 12 Ratio of IC50 for human ERalpha to IC50 for human ERbeta ChEMBL. 17448656
Ratio IC50 (binding) > 13 Selectivity for human recombinant ERbeta over ERalpha ChEMBL. 17890084

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

2 literature references were collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.